Gene expression in peripheral blood of patients with hypertension and patients with type 2 diabetes

Journal of Cardiovascular Medicine

Volumn 15, Issue 9, 2014, Pages 702-709

  Stoynev, Nikolay ^a   Dimova, Ivanka ^a   Rukova, Blaga ^a   Hadjidekova, Savina ^a   Nikolova, Dragomira ^a   Toncheva, Draga ^a   Tankova, Tsvetalina ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

atherosclerosis; gene expression; hypertension; type 2 diabetes

Indexed keywords

PLASMA PROTEIN;

ADULT; ANTHROPOMETRY; BIOSYNTHESIS; BLOOD; COMPLICATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROCEDURES; UPREGULATION;

ADULT; ANTHROPOMETRY; BLOOD PROTEINS; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; UP-REGULATION;

EID: 84905897784     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32835dbcc8     Document Type: Article

References (48)

1. Hingorani AD, Brown MJ. Identifying the genes for human hypertension. Nephrol Dial Transplant 1996; 11: 575-586
2. Zhang HM, Zhang XL, Zhou X, Li D, Gu JG, Wu JJ. Mechanism linking atherosclerosis and type 2 diabetes: Increased expression of scavenger receptor CD36 in monocytes. Chin Med J (Engl) 2005; 118: 1717-1722
3. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF consultation. Geneva; WHO; 2006
4. The Task Force for the Management of Arterial Hypertension of the European Society for Hypertension (ESH) and of the European Society of Cardiology (ESC): 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28: 1462-536
5. Gracia-Sancho J, Russo L, García-Calderó H, García-Pagán JC, García-Cardeña G, Bosch J. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. Gut 2011; 60: 517-524
6. Guignabert C, Alvira CM, Alastalo TP, et al. Tie2-mediated loss of peroxisome proliferator-Activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1082-L1090
7. Kelly DJ, Cox AJ, Gow RM, Zhang Y, Kemp BE, Gilbert RE. Plateletderived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension 2004; 44: 195-202
8. Coll T, Alvarez-Guardia D, Barroso E, et al. Activation of peroxisome proliferator-Activated receptor-{delta} by GW501516 prevents fatty acidinduced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells. Endocrinology 2010; 151: 1560-1569
9. Yoshizumi M, Kourembanas S, Temizer DH, Cambria RP, Quertermous T, Lee ME. Tumor necrosis factor increases transcription of the heparinbinding epidermal growth factor-like growth factor gene in vascular endothelial cells. J Biol Chem 1992; 267: 9467-9469
10. Asakawa H, Miyagawa J, Higashiyama S, et al. High glucose and hyperosmolarity increase heparin-binding epidermal growth factor-like growth factor (HB-EGF) production in cultured human aortic endothelial cells. Cell Biochem Funct 1996; 14: 181-186
11. Shah BH, Catt KJ. Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy. Trends Endocrinol Metab 2004; 15: 241-243
12. Bobryshev YV, Cherian SM, Inder SJ, Lord RS. Neovascular expression of VE-cadherin in human atherosclerotic arteries and its relation to intimal inflammation. Cardiovasc Res 1999; 43: 1003-1017
13. Porreca E, Di Febbo C, Mincione G, et al. Increased transforming growth factor-beta production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension 1997; 30 (1 Pt 1): 134-139
14. Gedikli O, Ozturk S, Yilmaz H, et al. Relationship between arterial stiffness and myocardial damage in patients with newly diagnosed essential hypertension. Am J Hypertens 2008; 21: 989-993
15. Otsuka F, Yamauchi T, Kataoka H, Mimura Y, Ogura T, Makino H. Effects of chronic inhibition of ACE and AT1 receptors on glomerular injury in Dahl salt-sensitive rats. Am J Physiol 1998; 274: R1797-R1806
16. Kim S, Ohta K, Hamaguchi A, Miura K, Yukimura T, Iwao H. Suppression of vascular transforming growth factor-beta1 and extracellular matrix gene expressions by cilazapril and nifedipine in hypertensive rats. Clin Exp Pharmacol Physiol Suppl 1995; 22: S355-S356
17. Haltern G, Peiniger S, Bufe A, Reiss G, Gülker H, Scheffold T. Comparison of usefulness of heart-Type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Cardiol 2010; 105: 1-9
18. Pé rez P, Moore-Carrasco R, Gonzá lez D, Fuentes E, Palomo I. Gene expression of adipose tissue, endothelial cells and platelets in subjects with metabolic syndrome (Review). Mol Med Rep 2012. doi: 10.3892/mmr.2012.785 [Epub ahead of print]
19. Peter K, Nawroth P, Conradt C, et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17: 505-512
20. Arvanitis DA, Flouris GA, Spandidos DA. Genomic rearrangements on VCAM1, SELE, APEG1 and AIF1 loci in atherosclerosis. J Cell Mol Med 2005; 9: 153-159
21. Cosson E, Brinquier AF, Paries J, et al. Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance. Diabetes Metab 2005; 31: 47-54
22. Tamakoshi A, Suzuki K, Lin Y, et al. JACC Study Group: Relationship of sFas with metabolic risk factors and their clusters. Eur J Clin Invest 2010; 40: 527-533
23. Troyanov S, Hé bert MJ, Masse M, Vigneault N, Sirois I, Madore F. Soluble Fas: A novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis 2003; 41: 1043-1051
24. Kanauchi M, Nishioka H, Dohi K. Diagnostic significance of urinary fibronectin in diabetic nephropathy. Nihon Jinzo Gakkai Shi 1995; 37: 127-133
25. Suzuki D. Measurement of the extracellular matrix in glomeruli from patients with diabetic nephropathy using an automatic image analyzer. Nihon Jinzo Gakkai Shi 1994; 36: 1209-1215
26. Chen P, Jou YS, Fann CS, et al. Lipoprotein lipase gene is linked and associated with hypertension in Taiwan young-onset hypertension genetic study. J Biomed Sci 2005; 12: 651-658
27. Chen P, Jou YS, Fann CS, et al. Lipoprotein lipase variants associated with an endophenotype of hypertension: Hypertension combined with elevated triglycerides. Hum Mutat 2009; 30: 49-55
28. Yamashita H, Bharadwaj KG, Ikeda S, et al. Cardiac metabolic compensation to hypertension requires lipoprotein lipase. Am J Physiol Endocrinol Metab 2008; 295: E705-E713
29. Pou J, Martínez-Gonzá lez J, Rebollo A, et al. Type II interleukin-1 receptor expression is reduced in monocytes/macrophages and atherosclerotic lesions. Biochim Biophys Acta 2011; 1811: 556-563
30. Reith A, Booth NA, Moore NR, Cruickshank DJ, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, preeclampsia and hydatidiform mole. Br J Obstet Gynaecol 1993; 100: 370-374
31. Sartori MT, Serena A, Saggiorato G, et al. Variations in fibrinolytic parameters and inhibin-A in pregnancy: Related hypertensive disorders. J Thromb Haemost 2008; 6: 352-358
32. Volcik KA, Catellier D, Folsom AR, Matijevic N, Wasserman B, Boerwinkle E. SELP and SELPLG genetic variation is associated with cell surface measures of SELP and SELPLG: The Atherosclerosis Risk in Communities Carotid MRI Study. Clin Chem 2009; 55: 1076-1082
33. Romzova M, Hohenadel D, Kolostova K, et al. NFkappaB and its inhibitor IkappaB in relation to type 2 diabetes and its microvascular and atherosclerotic complications. Hum Immunol 2006; 67: 706-713
34. Langham RG, Kelly DJ, Maguire J, Dowling JP, Gilbert RE, Thomson NM. Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrol Dial Transplant 2003; 18: 1392-1396
35. Takemoto M, Yokote K, Nishimura M, et al. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20: 624-628
36. Takemoto M, Yokote K, Yamazaki M, et al. Enhanced expression of osteopontin by high glucose. Involvement of osteopontin in diabetic macroangiopathy. Ann N Y Acad Sci 2000; 902: 357-363
37. Kase S, Yokoi M, Saito W, et al. Increased osteopontin levels in the vitreous of patients with diabetic retinopathy. Ophthalmic Res 2007; 39: 143-147
38. Graf K, Do YS, Ashizawa N, et al. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 1997; 96: 3063-3071
39. Lamers ML, Gimenes FA, Nogueira FN, Nicolau J, Gama P, Santos MF. Chronic hyperglycaemia increases TGFbeta2 signaling and the expression of extracellular matrix proteins in the rat parotid gland. Matrix Biol 2007; 26: 572-582
40. Nikkari ST, Geary RL, Hatsukami T, et al. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy. Am J Pathol 1996; 148: 777-783
41. Kong YZ, Huang XR, Ouyang X, et al. Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques. Cardiovasc Res 2005; 65: 272-282
42. Alla F, Kearney-Schwartz A, Radauceanu A, Das Dores S, Dousset B, Zannad F. Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur J Heart Fail 2006; 8: 147-153
43. Walden CC, Hegele RA. Apolipoprotein E in hyperlipidemia. Ann Intern Med 1994; 120: 1026-1036
44. Lin RY, Choudhury RP, Cai W, et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003; 168: 213-220
45. Yamamoto K, Shimano H, Shimada M, et al. Overexpression of apolipoprotein E prevents development of diabetic hyperlipidemia in transgenic mice. Diabetes 1995; 44: 580-585
46. Bard JM, Charles MA, Juhan-Vague I, et al. BIGPRO Study Group: Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: The biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. Arterioscler Thromb Vasc Biol 2001; 21: 407-414
47. Liu F, Brezniceanu ML, Wei CC, et al. Overexpression of angiotensinogen increases tubular apoptosis in diabetes. J Am Soc Nephrol 2008; 19: 269-280
48. Khalfaoui T, Beltaief O, Meddeb Amel O. Expression des facteurs apoptotiques Bax et Bcl-2 dans la conjonctive des patients diabé tiques: É tude pré liminaire. J Fr Ophthalmol 2007; 30: 799-806